









Markets
/
Stocks
/
nasdaq-gern
/

Geron Corp

GERN

1.530USD

+0.070+4.79%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

976.68MMarket Cap

LossP/E TTM



Geron Corp

1.530

+0.070+4.79%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Geron Corp

Currency: USD Updated: 2026-02-06

Key Insights

Geron Corp's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 39 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 3.17.In the medium term, the stock price is expected to trend up.The company has been performing well in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Geron Corp's Score

Industry at a Glance

Industry Ranking

39 / 392

Overall Ranking

144 / 4521

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Geron Corp Highlights

StrengthsRisks

Geron Corporation is a commercial-stage biopharmaceutical company. The Company develops first-in-class telomerase inhibitor, RYTELO (imetelstat) for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes (lower-risk MDS), with transfusion-dependent (TD) anemia requiring four or more red blood cell units over eight weeks who have not responded to or have lost response to or are ineligible for erythropoiesis-stimulating agents (ESAs). RYTELO is supported by the high unmet need in lower-risk MDS, including the observed benefit of RYTELO in difficult-to-treat subpopulations, such as patients with high transfusion burden and ring sideroblast negative (RS-) patients. It is also engaged in conducting a pivotal Phase III clinical trial of imetelstat in JAK-inhibitor relapsed/refractory myelofibrosis (R/R MF), as well as studies in other myeloid hematologic malignancies.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 12818.46% year-on-year.

Growing

The company is in a growing phase, with the latest annual income totaling USD 76.99M.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 76.99M.

Undervalued

The company’s latest PE is -12.85, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 517.62M shares, decreasing 29.75% quarter-over-quarter.

Held by Joel Greenblatt

Star Investor Joel Greenblatt holds 38.83K shares of this stock.

Analyst Rating

Based on 7 analysts

Buy

Current Rating

3.167

Target Price

+116.90%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of Geron Corp is 8.40, ranking 44 out of 392 in the Biotechnology & Medical Research industry. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 47.23M, representing a year-over-year increase of 67.05%, while its net profit experienced a year-over-year increase of 30.32%.

Score

Industry at a Glance

Previous score

8.40

Change



Financials

6.49

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.87

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.66

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Geron Corp's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of Geron Corp is 7.00, ranking 189 out of 392 in the Biotechnology & Medical Research industry. Its current P/E ratio is -12.85, which is -100.00% below the recent high of 0.00 and -14.97% above the recent low of -14.78.

Score

Industry at a Glance

Previous score

7.00

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 39/392

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

The current earnings forecast score of Geron Corp is 7.43, ranking 291 out of 392 in the Biotechnology & Medical Research industry. The average price target is 4.00, with a high of 5.00 and a low of 1.00.

Score

Industry at a Glance

Previous score

7.43

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 7 analysts

Buy

Current Rating

3.167

Target Price

+116.90%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

542

Total

Median

Average

Company name

Ratings

Analysts

Geron Corp

GERN

CRISPR Therapeutics AG

CRSP

argenx SE

ARGX

IQVIA Holdings Inc

IQV

Intellia Therapeutics Inc

NTLA

Beigene Ltd

ONC

...

109

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of Geron Corp is 8.14, ranking 66 out of 392 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 1.65 and the support level at 1.33, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.68

Change

1.46

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(2)

Buy(3)

Indicators

Value

Direction

MACD(12,26,9)

0.027

Buy

RSI(14)

62.966

Neutral

STOCH(KDJ)(9,3,3)

73.052

Neutral

ATR(14)

0.089

High Vlolatility

CCI(14)

119.986

Buy

Williams %R

15.625

Overbought

TRIX(12,20)

0.388

Sell

StochRSI(14)

57.241

Buy

Moving Average

Sell(0)

Neutral(0)

Buy(6)

Indicators

Value

Direction

MA5

1.502

Buy

MA10

1.433

Buy

MA20

1.390

Buy

MA50

1.341

Buy

MA100

1.292

Buy

MA200

1.337

Buy

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of Geron Corp is 7.00, ranking 86 out of 392 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 81.09%, representing a quarter-over-quarter decrease of 0.93%. The largest institutional shareholder is The Vanguard, holding a total of 35.54M shares, representing 5.57% of shares outstanding, with 4.22% increase in holdings.

Score

Industry at a Glance

Previous score

7.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

RA Capital Management, LP

60.38M

Deep Track Capital LP

41.10M

-4.43%

BlackRock Institutional Trust Company, N.A.

39.98M

-7.79%

The Vanguard Group, Inc.

Star Investors

34.30M

-3.36%

Vivo Capital, LLC

27.23M

State Street Investment Management (US)

26.62M

+12.64%

Goldman Sachs & Company, Inc.

20.63M

+123.23%

Soleus Capital Management, L.P.

17.29M

+7.13%

Vestal Point Capital, LP

17.23M

-27.55%

Citadel Advisors LLC

15.71M

+30.49%

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Geron Corp is 5.19, ranking 53 out of 392 in the Biotechnology & Medical Research industry. The company's beta value is 0.61. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.